Trial Profile
A Phase I Study of Veliparib in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2018
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Gemcitabine
- Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Abbott Laboratories; AbbVie
- 15 Jan 2018 Results published in the Gynecologic Oncology
- 24 Aug 2016 Status changed from active, no longer recruiting to completed.
- 20 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.